Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.

2 patients (brother and sister, 41 and 39 years of age) with apolipoprotein C-II deficiency syndrome, marked elevation of plasma triglycerides and chylomicrons, decreased LDL and HDL, and a type I lipoprotein phenotype.

Infusion of normal plasma or injection of a biologically active synthesized 44-79 amino acid residue peptide fragment of apo C-II.

Reduction in plasma triglycerides and triglyceride-rich lipoproteins.surrogate